Product image of Melleva (Ethinylestradiol, Levonorgestrel) supplied by GNH India

Melleva

Active Ingredient:
Ethinylestradiol, Levonorgestrel
Origin:
EU

Melleva (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Melleva, is a combined oral contraceptive presented as a tablet for oral use. It works together with levonorgestrel to prevent pregnancy and to help regulate menstrual cycles in women of reproductive age.

GNH India supplies Melleva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Manufacturer / TM Owner

Exeltis Healthcare S.L

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Melleva is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle.
  • Contraception: Prevents pregnancy by suppressing ovulation, thickening cervical mucus, and altering the endometrium.
  • Regulation of menstrual cycles: Provides cycle control and reduces irregular bleeding.
  • Premenstrual syndrome (PMS) symptom relief: May lessen mood swings, bloating, and breast tenderness associated with the luteal phase.

How It Works

  • Ethinylestradiol and levonorgestrel bind to estrogen and progesterone receptors, respectively, suppressing the hypothalamic‑pituitary‑ovarian axis. This inhibition reduces the release of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), preventing follicular development and ovulation. The progestin component also thickens cervical mucus and induces endometrial changes that hinder implantation.

Side Effects

Melleva may cause a range of adverse reactions. Patients should be aware of both frequent and rare events.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: tension‑type or migraine‑like.
  • Breast tenderness: temporary swelling or soreness.
  • Spotting or breakthrough bleeding: irregular light bleeding.
  • Mood changes: irritability or mild depressive symptoms.
  • Weight gain: modest increase in body weight.

Serious or Rare Side Effects

  • Deep vein thrombosis: blood clot formation in the legs.
  • Pulmonary embolism: clot migration to the lungs.
  • Stroke: cerebrovascular accident due to clot or hemorrhage.
  • Hepatic adenoma: benign liver tumor.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Visual disturbances: sudden loss of vision or blurred sight.

Precautions & Warnings

Before prescribing Melleva, clinicians should evaluate patient history and risk factors.

  • Contraindicated in women with a history of thromboembolic disorders: avoid use.
  • Caution in smokers over 35 years old: increased cardiovascular risk.
  • Monitor liver function in patients with hepatic disease: adjust therapy as needed.
  • Assess for migraine with aura: consider alternative contraception.
  • Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Melleva can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Anticoagulants (e.g., warfarin): may reduce contraceptive effectiveness.
  • Certain antiepileptic drugs (e.g., carbamazepine, phenytoin): increase hormone metabolism.
  • Rifampicin or other strong enzyme inducers: lower plasma hormone levels.

Moderate Interactions (Monitor Closely)

  • Antifungal agents (e.g., ketoconazole): may increase hormone concentrations.
  • St. John’s wort: may modestly reduce contraceptive efficacy.

Frequently Asked Questions

Melleva contains the hormones ethinylestradiol and levonorgestrel and is prescribed as a combined oral contraceptive. It is used to prevent unintended pregnancy and to help regulate menstrual cycles in women of reproductive age.

Ethinylestradiol binds to estrogen receptors and, together with levonorgestrel, suppresses the hypothalamic‑pituitary‑ovarian axis. This reduces luteinising hormone and follicle‑stimulating hormone release, preventing ovulation, while also thickening cervical mucus and altering the endometrium to impede implantation.

The specific dosing regimen for Melleva is determined by the prescribing clinician based on the product label and individual patient factors. Typically, a daily tablet is taken for a set cycle, but the exact schedule must be provided by the prescriber.

Melleva is intended for use in women who are not pregnant. If pregnancy occurs, the product should be discontinued. Use while breastfeeding is generally not recommended unless the benefits outweigh potential risks; a healthcare professional should be consulted.

To order Melleva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Melleva combines ethinylestradiol with levonorgestrel, a widely used progestin. Its efficacy and safety profile are comparable to other estrogen‑progestin pills, though individual tolerability may vary. Compared with newer progestins, levonorgestrel offers a well‑characterised safety record and reliable cycle control.

Melleva tablets should be stored at ambient temperature below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Melleva is taken orally as a tablet with water, usually at the same time each day. Patients should follow the prescribing clinician’s instructions regarding the number of tablets per cycle and any hormone‑free interval.

The most serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, and stroke, as well as rare hepatic adenomas and severe allergic reactions. Patients should seek immediate medical attention if they experience leg pain, sudden shortness of breath, severe headache, or signs of an allergic reaction.

Melleva is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. It should also be avoided by smokers over 35 years of age and by individuals with migraine with aura unless an alternative method is chosen.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT